Search Results

Hillhurst Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing liquid drug products containing therapeutic gases, announced the award of an up to $5 million HEAL Initiative grant from the National Institutes of Health.

Hillhurst Biopharmaceuticals, Inc. announced the completion of a financing that, together with non-dilutive sources, funds Phase 2a clinical studies in sickle cell disease and in a second clinical indication.

Hillhurst Biopharmaceuticals, Inc. today announced the award of an approximately $3 million Phase 2b SBIR grant from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.

Hillhurst Biopharmaceuticals, Inc. (“Hillhurst”) today announced that the last participant has completed the study protocol of its U.S. Phase 1 clinical trial of HBI-002, an oral low dose carbon monoxide (CO) therapeutic candidate.

Biopharmaceutical Market Outlook 2024-2032:

Hillhurst Biopharmaceuticals, Inc. (“Hillhurst”), a clinical-stage biopharmaceutical company focused on developing oral therapies enabling the therapeutic use of low dose carbon monoxide (CO), today announced that the company has received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) permitting the company to begin its Phase 1 trial for HBI-002,

Provectus Biopharmaceuticals, Inc. announced that its 2024 annual stockholder meeting, including meeting activities and a company update, will be accessible by Zoom Webinar.